NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma.

The purpose of this study is to determine if recurrent glioblastoma can be shrunk or stabilized by adding immune therapy drugs to the usual radiation therapy and if this approach is better or worse than the usual approach for recurrent glioblastoma (The usual approach is treatment with surgery, radiation, or chemotherapy.).

Learn more about the NRG-BN010 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Alliance-A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma.

This study is being done to find out if treatment with the combination of immunotherapy drugs nivolumab and ipilimumab is better or worse than the usual approach for recurrent glioblastoma with elevated mutational burden.

Learn more about the Alliance-A071702 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Alliance-N0577: Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

This study has been developed to treat people with anaplastic or low-grade glioma brain tumors which are positive for (contain) the 1p/19q co-deletion and IDH tumor markers.

Learn more about the Alliance-N0577 trial or call the Reading Hospital Protocol Office at 484-628-8193.

TJU-16D.651: Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study

This is a study to evaluate the impact of radiosurgery on neurological function, particularly short-term memory.

Learn more about TJU-16D.651 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-BN007: A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma.

The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy plus the immune therapy drugs ipilimumab and nivolumab to treat MGMT unmethylated glioblastoma brain tumors.

Learn more about the NRG-BN007 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma.

The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine) to treat MGMT methylated glioblastoma brain tumors.

Learn more about the NRG-BN011 trial or call the Reading Hospital Protocol Office at 484-628-8193.